Cardiology & Diuretic Tablet Franchise in Ahmedabad

Eplerenone + Torasemide Tablet Supplier in Mumbai

Cardio & Hypertension Tablet Distributor in Delhi

Heart Care Pharma Franchise in Bangalore

Cardiac Tablet Stockist in Hyderabad
Diuretic & Cardio Tablet Manufacturer & Exporter in Chandigarh

Home/Products /eplerenone-25mg-torasemide-10mg-tablet

Eplemore T Tablet

Composition : Eplerenone (25mg) + Torasemide (10mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Eplemore T Tablet contains Eplerenone 25 mg and Torasemide 10 mg, a dual-action cardiovascular formulation designed for effective management of hypertension, edema, and heart failure.

Eplerenone acts as a selective aldosterone antagonist, reducing fluid retention, blood pressure, and cardiac workload, while Torasemide works as a loop diuretic, promoting excretion of excess water and sodium, alleviating edema and related cardiac stress.

Clinically, Eplemore T Tablet is indicated for hypertension, chronic heart failure, and fluid overload conditions, providing enhanced cardiac function, reduced swelling, and improved patient comfort. Its tablet formulation ensures accurate dosing, stability, and patient compliance.

From a business perspective, Eplemore T Tablet strengthens the cardiology therapy segment, widely used in cardiology clinics, hospitals, and specialty heart care centers, offering consistent demand, repeat prescriptions, and strong prescriber confidence.

Read More

About the Product

Eplemore T Tablet contains Eplerenone 25 mg and Torasemide 10 mg, a dual-action cardiovascular formulation designed for effective management of hypertension, edema, and heart failure.

Eplerenone acts as a selective aldosterone antagonist, reducing fluid retention, blood pressure, and cardiac workload, while Torasemide works as a loop diuretic, promoting excretion of excess water and sodium, alleviating edema and related cardiac stress.

Clinically, Eplemore T Tablet is indicated for hypertension, chronic heart failure, and fluid overload conditions, providing enhanced cardiac function, reduced swelling, and improved patient comfort. Its tablet formulation ensures accurate dosing, stability, and patient compliance.

From a business perspective, Eplemore T Tablet strengthens the cardiology therapy segment, widely used in cardiology clinics, hospitals, and specialty heart care centers, offering consistent demand, repeat prescriptions, and strong prescriber confidence.

Common side effects may include dizziness, headache, mild gastrointestinal discomfort, increased urination, or fatigue. Rarely, hyperkalemia (elevated potassium), hypotension, or allergic reactions may occur.

Eplemore T Tablet is indicated for the management of hypertension, edema associated with heart failure, and other conditions requiring diuretic and aldosterone-blocking therapy. It helps control blood pressure, reduce swelling, and prevent complications related to fluid retention.

Use Eplemore T Tablet strictly as prescribed by a healthcare professional. Monitor blood pressure, kidney function, and serum electrolytes regularly. Avoid excessive potassium intake and inform your doctor of any kidney disorders or heart conditions. Discontinue use and seek medical advice if severe dizziness, irregular heartbeat, or other unusual symptoms occur.

Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.

Get in Touch

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our Successful network today.

Quick Navigation

1500+ Products

Our Divisions

All Therapeutics

Disclaimer: Pharma Insights are based on operational standards as of March 2026. All territories are subject to availability and Revised Schedule M compliance.